Gedeon Richter’s research and development spending was topped by biosimilar investment in the first nine months of this year, as the Hungarian firm continues to advance multiple candidates and support a growing portfolio of products.
Group R&D expenses were 17.1% higher at HUF42.8bn ($141m), according to figures just released by the company. Of that amount,...






